Browse Articles
Discover research articles across all indexed journals
Investigation on morphological and molecular fingerprints of penguin brain using label-free optical imaging and spectroscopic techniques
Abstract The morphology and molecular study of the penguin brain are crucial to define its survival in the extreme conditions of Antarctica. The present study focusses on extracting different optical parameters of the penguin brain using label-free optical imaging and spectroscopic techniques. In label-free optical imaging, we have used quantitative phase imaging, which provides morphological information about the neurons in brain tissue, giving the quantitative phase value of 5 to 20 radians corresponding to the 8 µm tissue section. In label-free spectroscopic techniques, we have used autofluorescence and Raman spectroscopy. Autofluorescence spectroscopy provides molecular information about nicotinamide dinucleotide, flavins, lipofuscins, and porphyrins in the brain’s spectral range of 420 nm to 700 nm. Raman spectroscopy provides multiple peaks associated with different molecules in the brain; among them, few signals are observed at approximately 1305 cm−1, 1448 cm−1, and 1661 cm−1, which correspond to vibrational modes indicative of vibrational features within lipids and protein structures, as well as the presence of amide groups within brain tissue constituents. All these techniques provide the microscopic and molecular fingerprint of the penguin brain, which can be useful for understanding penguin’s anatomical, physiological, and social behavior.
Decipher risk stratification of radiorecurrent prostate cancer: Correlative analysis of the F-SHARP trial of salvage reirradiation.
419 Background: A third of patients with biochemical recurrence after radiation (RT) have intraprostatic radiorecurrence (IPR) on PSMA PET/CT. Patients with IPR have worse metastasis-free survival - a surrogate for progression to lethal prostate cancer (PCa). We previously reported the results from our F-SHARP clinical trial that demonstrated salvage reirradiation using focal dose-escalated high dose rate (HDR) brachytherapy is safe and effective. Here, we examine the Decipher score to determine if it could be a tool to risk stratify patients with IPR. Methods: F-SHARP (NCT03312972) is a multi-institutional phase I/II trial of focal dose-escalated salvage HDR for IPR. Patients were recruited from 2017-2023 at 3 centers. Eligibility criteria included a history of localized PCa treated with any form of definitive RT and biopsy-proven IPR with no regional or distant metastasis. Of the 62 participants, 37 consented for the biomarker correlative study and 31 (50%) had sample data passing quality control for Decipher analysis (Veracyte, San Diego, CA). De-identified data from 146,940 patients tested (2016-2024) with the Decipher prostate genomic classifier were retrieved from the GRID registry (NCT02609269) and used to create a matched cohort based on NCCN risk at diagnosis. Univariable Cox proportional hazards models were used to compare oncologic, CTCAE v4.03 toxicity, and EPIC-26 hrQoL events by Decipher risk group. Results: The biomarker cohort had similar baseline characteristics to the overall trial cohort. 30% received ADT with initial RT (73% external beam, 27% LDR brachytherapy). At recurrence, 71% had high Decipher risk (median score 0.67) as compared to only 35% (median score 0.48) in the matched GRID cases (n=130,760). Median time from initial RT to enrollment in Decipher low (<0.45) was 16.9 years, compared to 8.0 and 7.4 years in the intermediate (0.45-0.6) and high (>0.6) score patients. Median follow up was 32.3 months. Decipher score was not associated with toxicity or quality of life post-HDR (all p>0.05). As depicted in the table, higher Decipher score was associated with an increased risk of biochemical progression-free survival (bFS; p=0.03), local recurrence-free survival (LRFS; p=0.04), and radiographic progression-free survival (rPFS; p=0.01). At 3 years, bPFS was 43% vs. 75%, LRFS was 58% vs. 100%, and rPFS was 42% vs. 100% for Decipher high vs. lower risk (<0.6). Conclusions: Salvage reirradiation is a growing indication for RT in PCa. This is the first use of genomic risk stratification in this setting. Nearly a third of patients with IPR have a lower Decipher risk score, and our data suggest especially favorable outcomes with salvage HDR. Future studies to determine how Decipher risk stratification can be used to tailor further treatment intensification with systemic therapy for those most at risk of reirradiation failure are warranted. Clinical trial information: NCT03312972 . Endpoint Hazard Ratio per 0.1 unit (95% CI) bPFS 1.70 (1.05-2.75) LRFS 2.30 (1.02-5.18) rPFS 2.47 (1.23-4.97)
Incidence of EMBARK and EAU high-risk biochemical recurrence and prostate cancer mortality: A real-life population-based study.
372 Background: The EMBARK trial proved the efficacy of enzalutamide plus leuprolide in patients with prostate cancer (PCa) who have had high-risk biochemical recurrence (BCR). Different criteria are currently used to define high-risk BCR. The aim of this study was to evaluate the incidence of several definitions of High-risk BCR after radical prostatectomy (RP) or radiotherapy (RT) and their association with PCa specific mortality (PCSM). Methods: Population-based study including 17,753 men undergoing RP (n=12,010) or RT (n=5743) with curative intent (cT1-3, cM0) and PSA follow-up in Stockholm between 2003 and 2021. Follow-up for all patients was until death, emigration, or end of the study period (December 31, 2021). Primary outcomes were the cumulative incidence of any BCR (RP: PSA≥ 0.2; RT: PSA≥ nadir+2) and high-risk BCR (according to EAU and Embark criteria) estimated using the Kaplan Mayer method and PCSM accounting for competing risk. Results: The 10-year cumulative incidences of any BCR, EAU, and Embark high-risk BCR were 25% (95% CI 24, 26), 10% (9, 11), 4% (3, 4) after RP and 20% (19, 22), 10% (9, 11) and 10% (9, 11) after RT. Median time from RP to high-risk BCR was 12.6 (5.8, 25.7) months for EAU criteria and 11.8 (5.1, 22.3) months for Embark criteria. Similarly median time from RT to high-risk BCR was 21.2 (11.3, 45.9) months for EAU criteria and 23.4 (14.3, 38.3) months for Embark criteria.After RP, the 10-year Cumulative incidences of PCSM were 11% (95% CI: 9, 13), 17% (14, 21) and 30% (24, 37) for any BCR, EAU and Embark high-risk BCR, respectively. After RT, the 10-year PCSM cumulative incidences were 39% (35, 44), 50% (45, 56) and 49% (42, 55), respectively. Conclusions: Incidence of High-Risk BCR vary according to the definition used and primary treatment. High risk BCR usually happen early after treatment and most patients with any PSA elevation will never experience High-risk BCR during the follow-up. Embark criteria currently represent the more stringent criteria with a very high risk of PCSM. Pattern of presentations of BCR, and high-risk BCR according to EAU and EMBARK criteria after radical prostatectomy or radiotherapy. Primary treatment Radical Prostatectomy Radiotherapy PSA> 0.2 N=2501 EAU High Risk BCR N=1119 EMBARK High Risk BCR N=386 PSA>Nadir + 2 N=836 EAU High Risk BCR N=427 EMBARK High Risk BCR N=456 Time frame, n (%) 0-1 year 660 (26.4%) 535 (47.8%) 199 (51.6%) 117 (14.0%) 117 (27.4%) 96 (21.1%) 1-3 years 757 (30.3%) 392 (35.0%) 139 (36.0%) 297 (35.5%) 171 (40.0%) 229 (50.2%) 3-5 years 463 (18.5%) 111 (9.9%) 29 (7.5%) 198 (23.7%) 79 (18.5%) 109 (23.9%) 5-7 years 286 (11.4%) 48 (4.3%) 10 (2.6%) 85 (10.2%) 23 (5.4%) 16 (3.5%) >7 years 335 (13.4%) 33 (2.9%) 9 (2.3%) 139 (16.6%) 37 (8.7%) 6 (1.3%) Time to BCR, n (%) 29.7 (11.3, 59.6) 12.6 (5.8, 25.7) 11.8 (5.1, 22.3) 36.6 (18.6, 62.4) 21.2 (11.3, 45.9) 23.4 (14.3, 38.3)
Genome-wide burden survival tests for patients with metastatic prostate cancer on androgen receptor-targeted therapies in the Million Veterans Program dataset.
251 Background: Literature suggests various genes influence metabolism and treatment response in prostate cancer. While the androgen receptor gene is the primary target for hormonal treatment, studies increasingly highlight the roles of genes in lipid metabolism and pharmacogenetics, including APOE, BGN, AHSG, CYP2D6, SLC2A4 , and HSD3B1 . Genes allowing androgens to enter cells more efficiently may increase therapy resistance, worsening outcomes in recurrent or metastatic disease. An understanding of biomarkers and resistance mechanisms is essential to address this issue. We conducted a genome-wide search for genes that exhibit an effect on survival in patients on androgen receptor-targeted therapies. Methods: We developed two models: Model 1 identified 5,107 patients with metastatic prostate cancer receiving androgen deprivation therapy; model 2 focused on a subgroup 2,240 patients on abiraterone. We performed 18,544 distinct gene-level tests across the human genome using all coding variants within each gene, analyzing rare (minor allele frequency <1%) loss-of-function variants, and rare loss-of-function and missense variants. All analyses used the Veterans Administration’s Million Veterans Program (MVP) whole genome Release2 genomic data (96K males). We conducted separate analyses for African and European ancestry subjects. Gene-level survival analysis was performed using the SeqMeta R package that performs burden, Skat, and Skat-O tests. A Bonferroni correction was applied for 82,567 tests, requiring p<6.06E-7 to establish significance and p<5.00E-6 for suggestive evidence. Individual survival analyses were conducted on all SNPs within each significant gene. Results: Gene-level tests identified OR1G1 (burden p=1.87E-7, OR=0.17), PCDHGB1 (burden p= 2.92E-07, OR=0.61) and CLPB (burden p=3.34E-07, OR=0.30) as significantly associated with prostate cancer survival, while SNX18 demonstrated a suggestive association (Skat-O p=3.40E-6) among European ancestry subjects in model 1. Among African ancestry subjects, the best performing gene was UBD (burden p= 2.61E-06, OR=0.76). Analyses of rare loss-of-function and loss-of-function or missense variants failed to achieve significant or suggestive evidence. Model 2 did not reveal any significant findings. Additional variant level survival analyses revealed 4 significant SNPs from UBD including chr6.29555893.C.A, chr6.29556082.G.C, chr6.29556095.A.G_A, chr6.29556226.A.G_A (1 copy HR 3.1, 2 copies HR 3.7, p <.05) and SNP chr5.54519665.A.C_A from gene SNX18 (1 copy HR 1.5 p <.05). Conclusions: Our results indicate variants within several genes may influence prostate cancer survival by causing resistance to androgen-receptor targeted therapies and warrant follow-up in external datasets for validation.
Effects of whole-body vibration training as an adjunct to conventional rehabilitation exercise on pain, physical function and disability in knee osteoarthritis: A systematic review and meta-analysis
Background Knee osteoarthritis (KOA) is a prevalent degenerative joint condition that impairs mobility and quality of life. While whole-body vibration training (WBVT) shows promise as an adjunct to conventional KOA rehabilitation, its efficacy remains unclear due to inconsistent clinical evidence. Objective To elucidate the combined effects of WBVT and rehabilitation exercise on pain, physical function, and disability in KOA management through a systematic review and meta-analysis. Methods A comprehensive search was conducted across eight electronic databases (PubMed, Web of Science, Embase, PEDro, SPORTDiscus, Scopus, ScienceDirect, and China National Knowledge Infrastructure) up to February 2024. Inclusion criteria were (i) randomized controlled trials comparing combined WBVT and rehabilitation exercise versus rehabilitation alone in KOA (ii) reported clinical outcomes (iii) human studies, and (iv) publications in English or Chinese. Trial quality was assessed using the PEDro scale and Cochrane risk-of-bias tool. The meta-analysis employed random-effects models in Review Manager 5.3 to account for heterogeneity, supported by sensitivity analyses for robustness and subgroup analyses on WBVT frequency effects. Results Sixteen RCTs comprising 589 participants were included. The systematic review found that WBVT combined with conventional rehabilitation significantly reduced pain and improved physical function in KOA patients. The meta-analysis quantified these effects, showing that WBVT significantly (i) reduced knee pain (MD = −0.43, 95% CI [−0.70, −0.16], p = 0.002), with greater reductions observed from high-frequency WBVT, and (ii) increased isokinetic knee peak torque compared to rehabilitation exercise alone. No significant differences were found in balance, functional mobility, and disability outcomes. Sensitivity analysis of high-quality trials supported these results. However, the heterogeneity among studies and variations in control group interventions warrant cautious interpretation. Conclusion WBVT seems to be effective in reducing pain and enhancing muscle strength in KOA patients when used in conjunction with conventional rehabilitation. Future high-quality RCTs must standardize WBVT protocols, emphasize long-term follow-up, and refine dosage for clinically meaningful outcomes. Systematic review registration: International prospective register of systematic reviews (PROSPERO CRD42024508386)
Factors associated with false-positive screening mammography in São Paulo, Brazil
Mevrometostat (PF-06821497) in combination with enzalutamide for androgen receptor pathway inhibitor (ARPI)-naïve patients with metastatic castration-resistant prostate cancer (mCRPC): The phase 3, randomized MEVPRO-2 trial.
TPS287 Background: Mevrometostat (PF-06821497) is a potent, selective inhibitor of the histone methyltransferase enhancer of zeste 2 (EZH2), which is canonically involved in epigenetic repression of target genes. In prostate cancer, EZH2 overexpression is associated with poor prognosis, contributing to disease progression through transcriptional repression of tumor suppressor genes and androgen receptor (AR) activation, co-regulation of AR-mediated transcriptional programs, and cell cycle deregulation through methylation of non-histone targets. Given the associations between EZH2 and the AR, the addition of an EZH2 inhibitor to ARPI is hypothesized to extend the duration of clinical response and delay antiandrogen resistance compared with ARPI alone. In a nonrandomized, phase 1 dose-escalation study, objective responses to mevrometostat with enzalutamide were observed in patients with CRPC and prior abiraterone or enzalutamide treatment (NCT03460977; Schweizer MT, et al. J Clin Oncol . 2024;42(16_suppl):5061). Despite guideline recommendations of treatment intensification with ARPIs or chemotherapy for metastatic castration-sensitive prostate cancer (mCSPC), many patients do not receive ARPIs at the mCSPC stage. MEVPRO-2 (NCT06629779) will evaluate mevrometostat plus enzalutamide compared with enzalutamide alone in ARPI-naïve patients with mCRPC. Methods: MEVPRO-2 is a global, double-blind, randomized, phase 3 trial. Key inclusion criteria are males, ≥18 years, with progressive mCRPC, castrate testosterone of ≤50 ng/dL, Eastern Cooperative Oncology Group performance status of 0 or 1, and life expectancy of ≥12 months. Patients with systemic treatments for mCRPC (except androgen deprivation therapy and first-generation antiandrogens) are excluded. Approximately 900 patients will be randomized 1:1 to receive mevrometostat (875 mg, twice daily) with enzalutamide (160 mg, once daily) or placebo with enzalutamide. The primary endpoint is blinded independent central review-assessed radiographic progression-free survival per Response Evaluation Criteria in Solid Tumours 1.1 (soft tissue) or Prostate Cancer Working Group 3 (bone). Key secondary endpoints are overall survival and time to pain progression (Brief Pain Inventory – Short Form question 3 or opioid use). Hazard ratios and 95% confidence intervals will be estimated using a Cox proportional hazard model, stratified by prior docetaxel and presence of hepatic metastases. P-values will be provided using a stratified log-rank test. Safety and tolerability will also be assessed. Clinical trial information: NCT06629779 .
Outcomes of different therapeutic modalities for patients with metachronous oligometastatic renal-cell carcinoma (RCC): Analyses of a single-institution database.
553 Background: There is limited data in the literature concerning the management of patients (pts) with metachronous oligometastatic RCC. This study aimed to compare survival outcomes with various therapeutic modalities from a referral center cohort database. Methods: Pts with recurrent RCC from previous radical surgery for localized tumor, presenting with ≤5 metastatic lesions, were retrospectively analyzed. The primary endpoint was progression-free survival (PFS). Secondary endpoints were overall survival (OS) and PFS from subsequent therapy (PFS2). Descriptive statistics and Cox-proportional hazard-regression models for PFS and OS were used. Survival rates were estimated with Kaplan-Meier method. P-values <0.05 were considered statistically significant. Results: In total, 142 pts were identified, treated from 02/2006 to 08/2023. 30 pts received active surveillance (AS), 48 metastasectomy (M), 30 stereotactic body radiotherapy (SBRT) and 34 first-line systemic therapy (1L). Median follow-up was 61.4 months (mo). There were no significant differences between groups according to age (p=0.29), ECOG performance status (p=0.99), Charlson Comorbidity Index (CCI) (p=0.81), International Metastatic RCC Database Consortium (IMDC) score (p=0.06) and time to metastatic relapse (p=0.27). The number of organs involved (NO) and the number of lesions (NL) were significantly different between groups with lower lesion counts for RT in both cases (p=0.02 and p<0.001, respectively), while sites of metastases (SM) did not differ (p=0.09). Subsequent therapies consisted of AS (2%), M (10.2%), SBRT (10%) and systemic therapy (77.5%). Median PFS was 14 mo for AS (95% CI: 9-26), 15 mo for M (95% CI: 10-49), 21 mo for RT (95% CI: 12-48), and 12 mo for 1L (95% CI: 10-16), with significant differences observed across treatment arms (p=0.026). No significant differences were found in OS (p=0.05) or in PFS2 (p=0.57). ECOG performance status was associated with OS (HR: 2.13, 95% CI: 1.34-3.11, p=0.002) but not with PFS (HR: 1.02, 95% CI: 0.75-1.40, p=0.85). No significant associations were found between CCI and either PFS or OS (HR: 0.94, p=0.16 and HR:1.12, p=0.19 respectively). Additionally, no associations were found between time of recurrence and neither PFS (HR: 0.99, 95% CI:0.99-1.00, p=0.07) nor OS (HR:0.99, 95% CI: 0.98-1.00, p=0.08). NO, SM and NL were not associated with either PFS or OS. Conclusions: The study highlights the importance of multidisciplinary discussions in pts with metachronous oligometastatic RCC, as there are potentially significant differences in PFS across treatment strategies. Limitations include retrospective nature, potential selection and confounding biases.
Use of urinary cell-free DNA methylation assay to identify tumor fraction for early detection and recurrence monitoring in urothelial carcinoma.
844 Background: Urothelial carcinoma (UC) remains one of the most common urologic cancers, presenting challenges in both initial diagnosis and follow-up due to the invasive nature of traditional diagnostic procedures. Urinary cell-free DNA (ucfDNA) analysis offers a non-invasive alternative, with DNA methylation patterns providing a promising avenue for identifying tumor-derived cfDNA. This study explores the utility of ucfDNA methylation-based tumor fraction (mTF) for early detection and monitoring recurrence in UC patients. Methods: A case-control study was conducted with 121 participants, analyzing ucfDNA from patients with pathologically confirmed malignant tumors and benign lesions. A panel of UC-specific methylation markers was developed to quantify tumor-derived ucfDNA in a tissue-agnostic manner. The methylation-based tumor fraction (mTF) was then correlated with reference circulating tumor DNA (ctDNA) levels and clinical urine cytology indicators. Results: Our analysis revealed a significantly higher mTF in UC patients compared to controls (Wilcoxon test, p-value = 3.3 x 10 -9 ). Utilizing mTF as an independent biomarker for distinguishing malignant from benign cases achieved a positive predictive value (PPV) of 92% and a negative predictive value (NPV) of 90%. Moreover, relapse signals (mTF > 0.005) were detected in follow-up urine samples from all patients (7/7) who had undergone transurethral resection of bladder tumor (TURBT). Conclusions: The urinary cfDNA methylation-based tumor fraction presents a promising non-invasive biomarker for both early detection and recurrence monitoring of urothelial carcinoma. This approach could significantly improve patient management by providing a valuable tool for diagnosis and ongoing surveillance, underscoring the need for innovative diagnostic strategies in UC.
Saikosaponin A alleviates depressive-like behavior induced by reserpine in mice by regulating gut microflora and inflammatory responses
Saikosaponin A (SSA), a key ingredient of Chaihu-Shugan-San, has been shown to possess anti-inflammatory, antioxidant and antidepressant properties. Therefore, the present study aimed to investigate the potential mechanism of action and the effect of SSA on reserpine-induced depressive-like symptoms in mice. Establishing mouse model of depression using intraperitoneal injection of reserpine (RSP). Forced swimming test, tail suspension test and sucrose preference test were used to assess depression-like behavior in mice. The results showed that mice exposed to RSP not only showed weight loss and depressive behavior, but also elevated levels of IL-1β and TNF-α, as well as upregulated levels of reactive oxygen species (ROS) and lipid peroxides in the hippocampus. Detection of changes in the intestinal flora of mice using 16S rRNA, it was observed that the intestinal flora changed following SSA treatment. Not only was there an increase in the overall abundance of the intestinal microbiota, but there was also a significant down-regulation of the Firmicutes and an up-regulation of the Verrucomicrobia at the phylum level. Furthermore, SSA treatment markedly improved depressive-like behavior induced by RSP, alleviated damage to the hippocampus, elevated levels of monoamine neurotransmitters, suppressed inflammatory factors in the hippocampus, reduced hippocampal oxidative stress, and restored gut microbiota disruption in RSP-induced mice. The findings propose that SSA has the potential to alleviate depressive symptoms in mice by enhancing monoamine neurotransmitter levels, suppressing hippocampal inflammation, and modifying gut microbial composition.
The role of gut microbiota at different developmental stages in the adaptation of the Etiella zinckenella to a plant host
Concomitant G-CSF use in maintaining an efficacious dose and safe delivery of docetaxel in combination with darolutamide in patients with metastatic hormone sensitive prostate cancer (mHSPC): ARASENS, a phase 3 study.
152 Background: In ARASENS, darolutamide (DARO) + androgen deprivation therapy (ADT) + docetaxel (DOC) significantly reduced risk of death by 32.5% vs placebo (PBO) + ADT + DOC in patients (pts) with mHSPC, with a similar incidence of treatment-emergent adverse events (TEAEs) between DARO and PBO treatment arms. DOC is associated with the risk of febrile neutropenia, which can be managed by DOC dose reduction and/or use of granulocyte colony stimulating factor (G-CSF). We report the impact of DOC dose intensity on the safety and efficacy of the ARASENS triplet regimen and evaluate the benefits of G-CSF use in maintaining effective dose and safe delivery of DOC. Methods: Pts were randomized to receive DARO 600 mg orally twice daily or PBO, with ADT + DOC. Baseline characteristics, G-CSF use, safety, overall survival (OS), and time to prostate-specific antigen (PSA) progression were analyzed according to DOC relative dose intensity (RDI; ≤85% vs >85%), defined as the ratio of DOC dose received vs protocol-defined full planned dose (75 mg/m 2 × 6 cycles). Results: Of the 1305 pts (DARO n=651; PBO n=654), 32 (2%) never received DOC or had no RDI data; 800 (60%) had DOC dose modifications. Of 1273 pts with DOC RDI data (DARO n=637; PBO n=636), >97% received an efficacious dose (RDI >80%), and use of DARO did not impact DOC RDI. Concomitant G-CSF was used in 48% (DARO) and 46% (PBO) of pts with DOC dose modifications vs 42% (DARO) and 45% (PBO) in the overall population, and was mainly used for secondary prophylaxis after first DOC dose in both the DOC dose modification population (DARO 184/186 [99%]; PBO 188/190 [99%]) and the overall population (DARO 269/272 [99%]; PBO 282/284 [99%]). G-CSF use was higher in pts with DOC RDI ≤85% (DARO 70%; PBO 74%) vs RDI >85% (DARO 39%; PBO 41%). Pt demographics and baseline disease characteristics were broadly similar between RDI ≤85% and >85% subgroups; >60% of pts with RDI ≤85% were from Asia Pacific. Incidences of grade ≥3 TEAEs/grade ≥3 neutropenia/grade ≥3 febrile neutropenia were higher with DOC RDI ≤85%, but DOC discontinuation rates were similar between RDI subgroups (≤85%: DARO 7%, PBO 11%; >85%: DARO 8%, PBO 11%). TEAEs leading to DOC dose modification were higher with DOC RDI ≤85% (DARO 93%; PBO 97%) vs RDI >85% (DARO 26%; PBO 25%). OS and time to PSA progression were similar between the RDI ≤85% and >85% subgroups within each treatment group. Conclusions: Appropriate DOC dose modification and G-CSF use allowed almost all pts (97%) to receive an efficacious dose of DOC, with no difference in OS and time to PSA progression for RDI ≤85% vs >85%. Addition of DARO to ADT + DOC did not increase DOC dose modification rates or G-CSF use. Clinical trial information: NCT02799602 .
A non-coding RNA based classifier for favorable outcomes in clinically organ confined bladder cancer.
831 Background: Long non-coding RNA (lncRNA)-based genomic profiling has suggested utility to identify a distinct tumor subgroup corresponding to a favorable prognosis in patients with bladder cancer. Here, we further evaluate a genomic classifier in a cohort of patients undergoing radical cystectomy (RC). Methods: Transcriptome-wide expression profiling using Decipher Bladder was performed on TURBT samples from a cohort of patients with high grade, clinically organ confined (cTa-T2N0M0) UC who subsequently underwent RC without any neoadjuvant therapy (n=226). LncRNA-based luminal favorable status was determined using a previously developed genomic classifier. The primary endpoint was overall survival (OS) following surgery. Secondary endpoints included cancer-specific mortality and upstaging at RC. Results: In the study, 134 patients were clinical NMIBC (cTa/Tis/T1) and 92 patients were cT2. We identified 60 patients with luminal favorable subtype, all of which showed robust gene expression patterns associated with less aggressive bladder cancer biology. On MVA, patients with the luminal favorable subtype (vs. without) were significantly associated with lower odds of upstaging to pT3+ disease (OR [95% CI] 0.32 [0.12-0.82], p = 0.02), any upstaging (OR [95% CI] 0.41 [0.20-0.83], p = 0.01), and any upstaging and/or pN+ (OR [95% CI] 0.50 [0.25-1.00], p = 0.05). Luminal favorable bladder cancer was significantly associated with better OS (HR 0.33 [95% CI 0.15-0.74], p=0.007). Conclusions: This study validates the performance of the genomic classifier for identifying urothelial carcinomas with a luminal favorable subtype, harboring less aggressive tumor biology.
Comparative assessment of pre- and post-COVID-19 pandemic nephrectomy outcomes for renal cell carcinoma: Analysis of the ACS-NSQIP registry.
466 Background: The COVID-19 pandemic placed significant strain on healthcare systems in the U.S. Public health directives aimed at mitigating the spread of new COVID-19 cases, such as regional stay-at-home orders, resulted in the cancellation or significant delay of many surgical cases. This study aimed to examine the impact of COVID-19 on surgical outcomes after elective nephrectomy in patients with renal cell carcinoma (RCC). Methods: The ACS NSQIP database for 2019 through 2021 was queried for adult patients with RCC undergoing partial nephrectomy (CPT codes 50240, 50543) or radical nephrectomy (CPT codes 50220, 50225, 50230, 50545, 50546). Patients were stratified into pre-pandemic (2019 Q1-Q4, 2020 Q1) and post-pandemic (2020 Q2-Q4, 2021 Q1-Q4) cohorts. Outcomes included total operation time, length of total hospital stay, unplanned reoperation, hospital readmission, prolonged stay in the hospital, urologic-specific complications (superficial incisional SSI, deep incisional SSI, organ/space SSI, wound disruption, acute renal failure, urinary tract infections), systemic complications (pneumonia, unplanned intubation, on ventilator for greater than 48 hours, stroke/CVA, cardiac arrest requiring CPR, myocardial infarction, bleeding transfusion, DVT/thrombophlebitis, sepsis, sepsis shock), and 30-day mortality. Results: A total of 19,102 patients met inclusion criteria, with 8,321 patients in the pre-pandemic cohort and 10,781 in the post-pandemic cohort. On univariate analysis, the post-pandemic cohort had longer operative times ( p <0.001), shorter length of total hospital stay (p<0.001), and a higher proportion of outpatient procedures ( p <0.001). The post-pandemic cohort also had a higher proportion of patients with an ASA Physical Status Classification of III or above ( p =0.003), diabetes mellitus ( p = 0.006), or CHF in the 30 days prior to surgery ( p <0.001). Multivariate analysis of 30-day complications and adverse outcomes revealed no significant difference between the two cohorts, except that patients who underwent partial nephrectomy in the pre-pandemic cohort experienced septic shock significantly more often than patients in the post-pandemic cohort (OR=4.19, 95% CI: 1.17-15.00, p =0.028). Conclusions: While the onset of the COVID-19 pandemic was associated with longer operative times, shorter hospital stays, and a higher proportion of outpatient procedures, there is no evidence that the pandemic worsened 30-day surgical outcomes after nephrectomy in patients with RCC. Multivariate adjusted analysis of 30-day complications and adverse events associated with radical and partial nephrectomy (reference group set as the post-pandemic cohort). Radical Nephrectomy Partial Nephrectomy OR [95% CI] P Value OR [95% CI] P Value Any complication 0.93[0.82-1.04] 0.201 1.01[0.88-1.17] 0.894 Death 0.97[0.58-1.67] 0.898 0.68[0.27-1.72] 0.420 Hospital readmission 0.86[0.71-1.04] 0.115 0.93[0.77-1.13] 0.480 Unplanned reoperation 0.83[0.61-1.13] 0.230 0.96[0.71-1.30] 0.773 Still in hospital > 30 days 1.07[0.45-2.54] 0.881 2.21[0.45-10.97] 0.332
Impact of the COVID-19 pandemic on outcomes of acute ischemic stroke patients treated with endovascular therapy: A multicenter Canadian study
Objective The novel coronavirus disease 2019 (COVID-19) pandemic led to the implementation of wide-ranging institutional infection control protocols. The purpose of this study is to determine the effect of the pandemic on outcomes of large vessel occlusion (LVO) acute ischemic stroke (AIS) patients treated with endovascular therapy (EVT). Materials and methods Data were obtained from prospectively collected quality improvement stroke databases at six Canadian comprehensive stroke centres from March 11, 2020 to March 11, 2021. This patient cohort was compared to pre-pandemic patients consecutively treated with EVT from March 11, 2019 to March 10, 2020. The primary outcome is a 90-day modified Rankin Score (mRS). The secondary outcomes are angiographic time metrics. Results A total of 1329 EVT patients (pre-pandemic n = 666) were included. The initial NIHSS was statistically significantly lower in the pandemic cohort. Other baseline patient characteristics were comparable between the two periods. Median (interquartile range, IQR) time from last seen normal (LSN) to emergency department (ED) (172 (68–316) vs 210 (97–382) min; p = 0.0001), LSN to puncture (235 (160–378) vs 280 (184–475); p < 0.0001), computed tomography (CT) to angiographic table (68 (44–108) vs 84 (57–125) min; p = 0.002), ED to angiographic table (65 (37–96) vs 80 (50–112) min; p = 0.001), CT to recanalization (117 (84–156) vs 130 (89–173) min; p = 0.038) and LSN to recanalization (279 (198–453) vs 327 (219–561) min; p = 0.002) were longer in the pandemic period as compared to the pre-pandemic. There were no significant differences in median time from angiographic table to arterial puncture (13 (8–19) vs 12 (9–16) min; p = 0.70) or arterial puncture to first pass (21 (14–31) vs 20 (14–30) min; p = 0.50). Patients were more likely to have favourable outcomes (mRS at 90 days score of ≤ 2) post-EVT pre-pandemic than pandemic (53% vs 44%; p = 0.02). Furthermore, analysis of the time interval from “LSN to arterial puncture” in relation to functional outcomes showed that the percentage of unfavorable outcomes increased among patients who underwent EVT within 240 minutes. Specifically, the rate of unfavorable outcomes rose from 32.9% to 42.9% (p = 0.37 for intervals under 150 minutes) and from 41.6% to 52.3% (p = 0.15 for intervals between 151 and 240 minutes) when comparing pre-pandemic to pandemic periods. However, the detrimental effect associated with the pandemic was diminished in patients who received EVT beyond 240 mins (p = 1.0). Conclusion In this multicenter study involving six Canadian stroke centers, patients exhibited a higher probability of unfavorable long-term functional outcomes following EVT during the pandemic period compared to those in the pre-pandemic cohort, particularly during the first year of the pandemic.
Improved image reconstruction from brain activity through automatic image captioning
ProstACT GLOBAL: A phase 3 study of <sup>177</sup> Lu-rosopatamab (TLX591) with and without the best standard of care for patients with PSMA expressing metastatic castration-resistant prostate cancer progressing despite prior treatment with a novel androgen axis drug.
TPS303 Background: The treatment of advanced prostate cancer (PC) is challenging, with undesirable side effects that impact patient quality of life. Radioimmunotherapy (RIT) can localize therapy to specific tumor cells in multiple organs to reduce or eliminate damage to normal tissue. The cell surface glycoprotein prostate-specific membrane antigen (PSMA) is an ideal therapeutic target as it is highly expressed by malignant prostate cells. There is a strong rationale for further investigation of the 177 Lu-labeled, chelator-conjugated antibody, 1 77 Lu-rosopatamab, as a potential first-line RIT candidate for the treatment of PC. Methods: This multinational, multicenter, prospective, randomized, open label phase 3 study will have 2 parts: a dosimetry and safety lead-in (n=30) and a randomized treatment expansion (n=490). In Part 1, patients will be divided into 3 groups (n=10 each) to receive 2 single intravenous (IV) injections of 76 millicuries (mCi) each, 14 days apart, of 177 Lu-rosopatamab with best standard of care (SoC) combinations with abiraterone, enzalutamide, or docetaxel to fully characterize biodistribution and safety profiles of 177 Lu-DOTA-rosopatamab + SoC combinations. SoC received will be determined prior to treatment with 177 Lu-rosopatamab. In Part 2, patients will be enrolled in a 2:1 ratio to receive either the best SoC or 2 single IV injections of 76 mCi each (equivalent to a 45 mCi/m 2 dose in a standard 1.7m 2 individual) of 177 Lu-rosopatamab, given 14 days apart, plus best SoC. SoC will be determined prior to randomization, and a change in planned SoC will not be permitted. Eligible patients must have PSMA-expressing metastatic castration-resistant PC (mCRPC) that have progressed despite prior therapy with either enzalutamide or abiraterone plus prednisone, and 1 line of prior taxane therapy or have refused or are ineligible for taxanes. Patients must have adequate organ function including at least 150x10 9 /L platelets, hemoglobin 10 g/dL, and have PSMA-positive disease on 68 Ga-PSMA-11 PET/CT imaging as confirmed by a central reader. Key exclusion criteria include small cell histology, increased risk of hemorrhage or bleeding, known brain or hepatic metastases, or history of stroke, seizure, or treatment with radioisotopes within 6 months prior to randomization. The primary endpoint is radiographic progression-free survival. Key secondary endpoint is OS. Additional secondary endpoints include 5-year overall survival, tumor objective response rate, time to symptomatic skeletal event, and health-related quality of life. Clinical trial information: NCT04876651 .
An online clustering algorithm predicting model for prostate cancer based on PHI-related variables and PI-RADS in different PSA populations.
328 Background: Prostate cancer is the most common male malignancy. Current diagnostic methods using single TPSA and PHI lack specificity. Some researches have created nomograms for predicting risk, but these are not easily visualized. Our study aims to find the best negative predictive value (NPV) for PHI, then build a clustering model to display prostate cancer risk categories, particularly useful for patients with PSA>20 and be actually applied in clinical work. Methods: We collected 708 patients in the training cohort and 143 in the validation cohort, divided into three groups based on their PSA levels. Next, we determined optimal and customized PHI cut-off values, calculated NPV and PPV, and selected logistic regression as the best method among several machine-learning algorithms. Subsequently, the significant variables were identified, and then a clustering algorithm was constructed. Finally, the model was validated and made available online for further clinical application. Results: The Optimal PHI cut-off lower limits for PSA>4, PSA4-20, PSA>20 subgroups were 23.85, 24.35, and 40.75, with upper limits of 142.9, 143, and 135.6, respectively. The clustering model of the optimal cohort for PSA>4 and PSA 4-20 sub-groups showed a superior Silhouette coefficients of 0.433 and 0.526 than that of the customized PHI cohort (0.432, 0.452). The PSA>20 subgroup owned the highest Silhouette coefficient of 0.572. The validation cohort showed AUC values of 0.761, 0.823, 0.833 for these 3 sub-groups, with accuracy rates of 88.81%, 90.38%, and 82.05%. Conclusions: In conclusion, our clustering model effectively categorizes patients into distinct risk groups with clear visualization and has demonstrated stability and reliability in the validation cohort, potentially aiding in early diagnosis of prostate cancer in clinical practice.
Efficacy and safety of nivolumab plus ipilimumab (Nivo/Ipi) in patients with metastatic variant histology renal cell carcinoma.
558 Background: Nivo/ipi is a standard of care first-line (1L) therapy for patients with metastatic clear-cell renal cell carcinoma (ccRCC) but its role in patients with metastatic variant histology RCC (vhRCC) has not been fully defined. Methods: We report a single-institution experience with nivo/ipi to treat 55 patients with metastatic vhRCC between Nov. 2017 and Feb. 2024 at MD Anderson Cancer Center. Tumor response was measured by blinded radiologists using RECIST v1.1. Descriptive statistics and the Kaplan-Meier method were used. Results: Twenty-five (45.5%) patients had papillary histology (pRCC), 12 (21.8%) patients had chromophobe (chRCC), and 18 (32.7%) patients had unclassified RCC (uRCC) (Table). Fifty-two (94.5%) patients received nivo/ipi in 1L. Sarcomatoid features (SF) were found in 20 (36.4%) cases. Overall response rate (ORR) was 48% (12/25) for pRCC, 25% (3/12) for chRCC, 27.8% (5/18) for uRCC, and 55% (11/20) across histologies with SF. Median progression-free survival (PFS) was 10.6 mo [95% CI: 2.8 – 22.8] in pRCC, 3.6 mo [95% CI: 0.9 – NE] in chRCC, and 3 mo [95% CI: 2.1 – 7] in uRCC. Six-month PFS milestone was 56% [95% CI: 36.3 – 75.7], 41.7% [95% CI: 21.7 – 56.1], and 47.2% [95% CI: 35.3– 59.1] in pRCC, chRCC and uRCC, respectively. Median overall survival (OS) was 36.7 mo [95% CI: 11.5 – 54.8] in pRCC, 25.7 mo [95% CI: 0.9 – NE] in chRCC, and 11.1 mo [95% CI: 6.5 – NE] in uRCC. Grade 3/4 immune-mediated adverse events (IMAEs) were noted in 17 (30.9%), including colitis (n=6), pneumonitis (n=3), hepatitis (n=3), nephritis (n=2), thyroiditis (n=1), pancreatitis (n=1), and thrombocytopenia (n=1). Targeted DNA sequencing in 26 patients identified the most frequent alterations, TP53 (42%), PTEN (23%) and TERT (23%), and distinct molecular profiles of pRCC and chRCC, with TERT mutations enriched in pRCC and TP53 mutations more common in chRCC. Conclusions: Nivo/ipi produced favorable outcomes in pRCC. Despite ORR of 25% and 27.8%, respectively, patients with chRCC and uRCC had short PFS, with inferior OS in patients with uRCC. IMAEs with nivo/ipi were consistent with published reports. Outcome pRCC(n=25) chRCC(n=12) uRCC(n=18) Total(n=55) Best Overall Response, n (%) CR 1 (4%) 0 (0%) 1 (5.6%) 2 (3.6%) PR 11 (44%) 3 (25%) 4 (22.2%) 18 (32.7%) SD 4 (16%) 3 (25%) 3 (16.7%) 10 (18.2%) PD* 6 (24%) 4 (33.3%) 8 (44.4%) 18 (32.7%) NE 3 (12%) 2 (16.7%) 2 (11.1%) 7 (12.7%) ORR in pts with SF, n (%) 4/6 (66.7%) 3/8 (37.5%) 4/6 (66.7%) 11/20 (55%) Median OS, mo [95% CI] 36.7 [11.5 – 54.8] 25.7 [0.9 – NE] 11.1 [6.5 – NE] 19.4 [11.5 – 36.7] 12-month PFS milestone (%) [95% CI] 31% [11.4 – 54.7] 25% [0.5 – 49.5] 16.7% [0 – 33.9%] 25% [13.1 – 36.9] Median follow-up, mo [95% CI] 35.1 [12.3 – 72.6] 51.4 [21.2 – 58.8] 33.5 [24.4 – 42.9] 35.1 [30.8 – 52.3] Median duration of response, mo [95% CI] 20.1 [8.3 - NE] 8 [8 – NE] 8.5 [2.9 – NE] 8.5 [8 – NE] Median time on treatment, mo [IQR] 2.9 [0.4 – 10.9] 2.6 [0.9 – 10.2] 2.1 [1.2 – 5.4] 2.1 [0.7 – 10.3]
Why are individuals tracing travel trends? A case study of City Walk in Malaysia
Studying the emerging travel trends of City Walk is a beneficial activity for young groups. However, there is a lack of research and understanding regarding the motivation and mechanism behind these trends, both in theory and practice. The aim of this study was to investigate the motivation of persons who follow the travel trend of City Walk and evaluate how behavioral intentions are formed by exploring the link between motivation and behavioral intention using the self-determination theory, and social influence theory. Social influence, variety seeking, and self-identification were extrinsic and intrinsic motivations of behavioral intention. A quantitative purposive survey approach was employed, wherein 315 young individuals aged 18 to 40 were recruited to respond. The findings derived from the partial least squares structural equation modeling demonstrate that extrinsic incentives related to social influence, variety seeking, and health care have a considerable impact on behavioral intention, and to some extent influence self-identification. Self-identification has a mediating role in the relationship between health care and behavioral intention. By examining both theoretical and practical aspects, it seeks to provide useful theoretical insights and practical contributions to advance research and industry in the field of rural tourism.